Lynn Wolff
Acute Care · Paoli, PANPI 1013231398
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,883 of the $3,340 with a category attached, or 86.3%. 27 manufacturers reported payments, led by AstraZeneca at 24.2% of the total. 2025 is the largest year on record at $2,243, more than ten times the $20 reported in 2021. Among acute care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 132 payments — averaging $25.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$807
- Actelion Pharmaceuticals US, Inc.$395
- Regeneron Healthcare Solutions, Inc.$341
- GSK$260
- Harmony Biosciences LLC$238
- Takeda Pharmaceuticals U.S.A., Inc.$207
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,88386%
- Education$45714%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $807 |
| Actelion Pharmaceuticals US, Inc. | 10 | $395 |
| Regeneron Healthcare Solutions, Inc. | 13 | $341 |
| GSK | 12 | $260 |
| Harmony Biosciences LLC | 5 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $207 |
| Viatris Specialty LLC | 7 | $169 |
| Mylan Specialty L.p. | 4 | $121 |
| Electromed, Inc. | 6 | $104 |
| Verona Pharma, Inc. | 3 | $91 |
| Axsome Therapeutics, Inc. | 3 | $84 |
| Grifols USA, LLC | 3 | $82 |
| United Therapeutics Corporation | 3 | $58 |
| ANI Pharmaceuticals, Inc. | 2 | $56 |
| Inspire Medical Systems, Inc. | 2 | $41 |
| Tactile Systems Technology Inc | 2 | $38 |
| Baxter Healthcare | 1 | $35 |
| Philips North America LLC | 2 | $32 |
| Pulmonx Corporation | 1 | $25 |
| Lilly USA, LLC | 1 | $23 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $22 |
| Insmed, Inc. | 1 | $22 |
| Inogen, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Breas Medical, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
How this compares
$3,340 in reported general payments places this provider in the 95th percentile of 872 acute care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $69,909 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $20,326 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $17,124 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $5,315 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 119 | $2,961 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $1,430 |
| Azelastine Hcl | 20 | $572 |
| Atorvastatin Calcium | 23 | $462 |
| Azithromycin | 32 | $402 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $334 |
| Losartan Potassium | 18 | $317 |
| Prednisone | 73 | $296 |
| Omeprazole | 17 | $292 |
| Pantoprazole Sodium | 18 | $254 |
| Rosuvastatin Calcium | 12 | $253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $260 | $87,03393 claims |
| AstraZenecaBreztri Aerosphere | $807 | $20,32628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 872 acute care providers in Pennsylvania.
Other acute care in Paoli
- Kari FlynnPaoli$6K
- Kristi MontrellaAltoona$111K
- Kathryn GreenPhiladelphia$92K
- Caroline PratzPhiladelphia$77K
- Donna KinzlerPittsburgh$25K
- Lisa JohnsonPottstown$25K
- Kathryn McParlaneMoon Township$21K
- Rebecca MarcantuonoPhiladelphia$17K
- Stephanie TothPhiladelphia$17K
- Kevin HaganAbington$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.